Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Gavin Clark-Gartner is an analyst at Evercore ISI Group. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/26/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 01/28/2025 | MNMD | Buy Now | Mind Medicine | $6.90 | 233.33% | Gavin Clark-Gartner41% | → $23 | Initiates | → Outperform | Get Alert |
| 12/20/2024 | CABA | Buy Now | Cabaletta Bio | $1.69 | 254.44% | Gavin Clark-Gartner41% | $15 → $6 | Downgrade | Outperform → In-Line | Get Alert |
| 11/21/2024 | ARGX | Buy Now | argenx | $587.70 | 20.13% | Gavin Clark-Gartner41% | $675 → $706 | Maintains | Outperform | Get Alert |
| 11/07/2024 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 130.95% | Gavin Clark-Gartner41% | $179 → $170 | Maintains | Outperform | Get Alert |
| 08/26/2024 | JSPR | Buy Now | Jasper Therapeutics | $4.99 | 1202.61% | Gavin Clark-Gartner41% | $65 → $65 | Maintains | Outperform | Get Alert |
| 08/19/2024 | FHTX | Buy Now | Foghorn Therapeutics | $3.97 | 403.78% | Gavin Clark-Gartner41% | → $20 | Initiates | → Outperform | Get Alert |
| 08/12/2024 | KRYS | Buy Now | Krystal Biotech | $194.00 | 6.19% | Gavin Clark-Gartner41% | $201 → $206 | Maintains | Outperform | Get Alert |
| 08/12/2024 | CABA | Buy Now | Cabaletta Bio | $1.69 | 786.11% | Gavin Clark-Gartner41% | $25 → $15 | Maintains | Outperform | Get Alert |
| 08/08/2024 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 143.17% | Gavin Clark-Gartner41% | $185 → $179 | Upgrade | In-Line → Outperform | Get Alert |
| 08/08/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $46.75 | 41.18% | Gavin Clark-Gartner41% | $62 → $66 | Maintains | Outperform | Get Alert |
| 07/12/2024 | ARGX | Buy Now | argenx | $587.70 | -9.31% | Gavin Clark-Gartner41% | $478 → $533 | Maintains | Outperform | Get Alert |
| 06/24/2024 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 151.32% | Gavin Clark-Gartner41% | $139 → $185 | Maintains | In-Line | Get Alert |
| 04/03/2024 | JSPR | Buy Now | Jasper Therapeutics | $4.99 | 1202.61% | Gavin Clark-Gartner41% | → $65 | Initiates | → Outperform | Get Alert |
| 02/20/2024 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 87.47% | Gavin Clark-Gartner41% | $108 → $138 | Maintains | In-Line | Get Alert |
| 12/21/2023 | ARGX | Buy Now | argenx | $587.70 | -25.81% | Gavin Clark-Gartner41% | $594 → $436 | Maintains | Outperform | Get Alert |
| 10/17/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $46.75 | 32.62% | Gavin Clark-Gartner41% | → $62 | Reinstates | → Outperform | Get Alert |
| 10/03/2023 | ACRS | Buy Now | Aclaris Therapeutics | $1.63 | 1249.69% | Gavin Clark-Gartner41% | → $22 | Initiates | → Outperform | Get Alert |
| 07/17/2023 | ARGX | Buy Now | argenx | $587.70 | -25.81% | Gavin Clark-Gartner41% | → $436 | Reinstates | → Outperform | Get Alert |
| 06/23/2023 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 88.83% | Gavin Clark-Gartner41% | → $139 | Downgrade | Outperform → Neutral | Get Alert |
| 05/30/2023 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 105.14% | Gavin Clark-Gartner41% | $173 → $151 | Maintains | Outperform | Get Alert |
| 05/30/2023 | CCCC | Buy Now | C4 Therapeutics | $2.17 | 360.83% | Gavin Clark-Gartner41% | $20 → $10 | Maintains | Outperform | Get Alert |
| 05/15/2023 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 135.02% | Gavin Clark-Gartner41% | $149 → $173 | Maintains | Outperform | Get Alert |
| 04/13/2023 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 102.42% | Gavin Clark-Gartner41% | → $149 | Maintains | Outperform | Get Alert |
| 03/01/2023 | SRPT | Buy Now | Sarepta Therapeutics | $73.61 | 132.31% | Gavin Clark-Gartner41% | $135 → $171 | Maintains | Outperform | Get Alert |
| 02/09/2023 | ABBV | Buy Now | AbbVie | $201.53 | -18.13% | Gavin Clark-Gartner41% | $159 → $165 | Maintains | Outperform | Get Alert |
| 12/20/2022 | ABBV | Buy Now | AbbVie | $201.53 | -23.58% | Gavin Clark-Gartner41% | $156 → $154 | Maintains | Outperform | Get Alert |
| 10/05/2022 | INBX | Buy Now | Inhibrx | $14.48 | 314.36% | Gavin Clark-Gartner41% | $54 → $60 | Maintains | Outperform | Get Alert |
